Gelatin-Based Electrospun Nanofibers Cross-Linked Using Horseradish Peroxidase for Plasmid DNA Delivery

Biomolecules. 2022 Nov 4;12(11):1638. doi: 10.3390/biom12111638.

Abstract

The delivery of nucleic acids is indispensable for tissue engineering and gene therapy. However, the current approaches involving DNA/RNA delivery by systemic and local injections face issues such as clearance, off-target distribution, and tissue damage. In this study, we report plasmid DNA (pDNA) delivery using gelatin electrospun nanofibers obtained through horseradish peroxidase (HRP)-mediated insolubilization. The nanofibers were obtained through the electrospinning of an aqueous solution containing gelatin possessing phenolic hydroxyl (Ph) moieties (Gelatin-Ph) and HRP with subsequent HRP-mediated cross-linking of the Ph moieties by exposure to air containing 16 ppm H2O2 for 30 min. Then, Lipofectamine/pDNA complexes were immobilized on the nanofibers through immersion in the solution containing the pDNA complexes, resulting in transfection and sustained delivery of pDNA. Cells cultured on the resultant nanofibers expressed genome-editing molecules including Cas9 protein and guide RNA (gRNA), resulting in targeted gene knock-in and knock-out. These results demonstrated the potential of Gelatin-Ph nanofibers obtained through electrospinning and subsequent HRP-mediated cross-linking for gene therapy and tissue regeneration by genome editing.

Keywords: electrospinning; gelatin; gene delivery system; horseradish peroxidase; nanofiber.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • DNA
  • Gelatin* / chemistry
  • Horseradish Peroxidase / chemistry
  • Horseradish Peroxidase / genetics
  • Horseradish Peroxidase / metabolism
  • Hydrogen Peroxide
  • Nanofibers* / chemistry
  • Plasmids / genetics

Substances

  • Gelatin
  • Horseradish Peroxidase
  • Hydrogen Peroxide
  • DNA

Grants and funding

This research was funded by the Japan Society for the Promotion of Science KAKENHI, Japan, grant number 21H04811; Project MEET, Osaka University Graduate School of Medicine and Mitsubishi Tanabe Pharma Corporation; JST SPRING, Japan, grant number JPMJSP2138; and Grant-In-Aid for JSPS Fellows, grant number 22J12600.